When: 50 SMA reclaim on volume with RSI>55

Then: upgrade to OVERWEIGHT

When: close <$1,055 on volume >4M shares

Then: downgrade to UNDERWEIGHT

When: clean beat with raised tirzepatide net-price guidance and FCF inflection

Then: upgrade to OVERWEIGHT

When: in-line quarter with continued FCF flat-line and gross-to-net deterioration

Then: maintain HOLD

When: miss with guidance cut

Then: downgrade to UNDERWEIGHT

HOLD with tightened risk controls: reduce position size by 25%, defer scaling in at 1,113 or 1,055 until after Q3 earnings resolve in October, and consider long LLY / short NVO pair trade to maintain GLP-1 exposure while reducing single-name volatility.

• Forward P/E of 24.9x requires 59% EPS growth to materialize—trailing P/E is 39.5x, price-to-book is 30.9x
• Bull case depends on six-variable dependency chain: volume expansion offsetting pricing erosion, GLP-1 scaling, $15B annual capex execution, $10B M&A pipeline integration, CMS and commercial payer coverage expansion
• Technical breakdown: five consecutive lower highs from 1,280 to 1,176, MACD declining 10 straight weeks, RSI washing out from 74 to 45, ATR expanded to 40 with 30-50 point daily ranges now the norm
• 200 SMA at 1,055 is not a cushion but the line where all momentum systems flip bearish simultaneously
• Volume thesis depends on payer decisions that have not been made: CMS Medicare coverage restricted, commercial prior authorization strict, IRA negotiation expanding
• Zepbound cost-savings study explicitly excluded the drug's own price—a credibility problem if payers use it to deny coverage expansion
• Ken Griffin position is one fund, one quarter, one position—not a trade signal; retail essentially silent with one passive Reddit mention in seven days
• Novo Nordisk oral GLP-1 is cheaper to manufacture, easier to distribute, and patients prefer pills over injections; NVO approval in China (LLY's largest growth geography) would be a structural margin headwind
• Beta of 0.506 measures correlation with S&P 500, NOT absolute downside; 8% pullback from 1,280 to 1,176 is not a low-volatility event; multiple compression in higher-for-longer rate regime is discount rate risk applying to any premium-multiple stock
• Hold and protect, not hold and pray—the aggressive analyst conflates conviction with caution

→ vs aggressive: Dismissing the 8-day technical decline as 'noise' ignores five consecutive lower highs, MACD declining 10 weeks, RSI washing from 74 to 45, and ATR expanded to 40—tape is signaling buyers who controlled 1,280 are now sellers controlling 1,176

→ vs aggressive: Treating pricing pressure as a 'solved problem' because management talked about it ignores that the Zepbound cost-savings study explicitly excluded the drug's own price from analysis, creating a credibility problem with payers and CMS

→ vs aggressive: Using the Ken Griffin position as a hold justification is narrative investing, not risk management—smart money flows are inputs, not trade signals, and one fund/quarter/position is not a green light

→ vs aggressive: Assuming NVO will remain 'permanently impaired' because their stock is down 70% is an assumption, not a fact—oral GLP-1 approval in China would be a structural margin headwind for LLY's entire franchise

→ vs aggressive: Using beta to dismiss downside risk is misleading—beta measures correlation with S&P 500, not absolute downside; the 8% pullback in eight days is not low volatility, and multiple compression in higher-for-longer rate regime is a different risk than market beta

→ vs aggressive: Pricing in 'perfection, not probability'—the six-variable dependency chain requires flawless execution across volume, GLP-1 scaling, capex, M&A integration, and payer coverage expansion simultaneously

HOLD with modest 10-15% trim, stop tightened to 1,080, scaled entry at 1,113 and 1,055 with technical confirmation, optional pair trade hedge

• Structural thesis intact: 48% revenue growth, 54% operating margin, 102% ROE, oncology diversification, Alzheimer's diagnostic win
• Technical damage is corrective not regime-changing: five consecutive lower highs, 10 EMA below 50 SMA, MACD histogram negative and deepening, RSI washed out from overbought in six sessions
• ATR expanded from 33 to 40 indicating elevated volatility regime requiring adjusted position sizing
• 200 SMA cushion of 11.4% provides structural support at 1,055
• Beta of 0.506 suggests below-market volatility sensitivity
• Modest trim of 10-15% reduces concentration risk without abandoning the position
• Stop tightened from 1,055 to 1,080 (roughly 8% downside from current levels) to take action before 200 SMA test
• Scale-in tiers at 1,113 and 1,055 require technical confirmation (RSI divergence versus prior swing low, MACD histogram flattening) rather than mechanical price-level entries
• Q3 earnings in October is a catalyst but calendar timing is too rigid; technical confirmation is preferred over binary event avoidance
• Long LLY/short NVO pair trade is optional hedge, not mandatory, depending on overall risk budget and gross exposure capacity
• Primary monitoring triggers: 50 SMA reclaim with rising volume (corrective phase ending), and Q3 earnings setup with confirmed MACD histogram turn and RSI above 55

→ vs aggressive: Dismissed technical damage as 'noise' — ATR expanded from 33 to 40, five consecutive lower highs, 10 EMA below 50 SMA, negative and deepening MACD histogram, and RSI washed out in six sessions indicate a regime of elevated volatility with sellers in control, not a single-session wobble

→ vs aggressive: Failed to address position sizing — when ATR is 40 and stop is 121 points away, risk per share is roughly 10% of position, which is excessive for a name trading at 30x price-to-book multiple in a regime with flashing yellow momentum indicators

→ vs conservative: 25% trim is arbitrary and overcorrects — the technical report's 25% heuristic is generic, but LLY's 0.506 beta, intact structural thesis, and 11.4% 200 SMA cushion warrant only a 10-15% trim that reduces concentration without implying fundamental doubt

→ vs conservative: Deferring all scale-ins until after Q3 earnings is too rigid — Q3 earnings is six weeks away, and LLY has a history of rallying into and through earnings on beats; deferring all adds accepts high probability of missing the entry for small probability of avoiding earnings drawdown

→ vs conservative: Pair trade idea is oversold as mandatory — adding long LLY/short NVO increases gross exposure, margin requirements, execution complexity, and adds separate binary event risk around NVO's oral pipeline; it should be flagged as optional, not required